Previous Article | Next Article 
Infect Immun, June 1998, p. 2640-2647, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Interleukin-15 Activates Proinflammatory and
Antimicrobial Functions in Polymorphonuclear Cells
Tiziana
Musso,1,*
Liliana
Calosso,2
Mario
Zucca,3
Maura
Millesimo,1
Manuela
Puliti,4
Silvia
Bulfone-Paus,5
Chiara
Merlino,1
Dianella
Savoia,3
Rossana
Cavallo,1
Alessandro Negro
Ponzi,1 and
Raffaele
Badolato6
Department of Public Health and
Microbiology,1
Postgraduate School of
Clinical Pathology, Department of Genetics, Biology and Medical
Chemistry,2 and
Department of Clinical
and Biological Sciences,3 University of Turin,
Turin,
Department of Experimental Medicine and Biochemical
Sciences, University of Perugia, Perugia,4 and
Department of Pediatrics, University of Brescia,
Brescia,6 Italy, and
Institute of
Immunology, Benjamin Franklin Medical Center, Free University,
Berlin, Germany5
Received 3 November 1997/Returned for modification 8 December
1997/Accepted 13 March 1998
 |
ABSTRACT |
Interleukin-15 (IL-15) is a recently discovered cytokine produced
by a wide range of different cell types including fibroblasts, keratinocytes, endothelial cells, and macrophages in response to
lipopolysaccharide or microbial infection. This suggests that IL-15 may
play a crucial role in the activation of phagocytic cells against
pathogens. We studied polymorphonuclear leukocyte (PMN) activation by
IL-15, evaluated as enhancement of PMN anti-Candida activity as well as IL-8 production, following stimulation with the
cytokine. The PMN response to IL-15 depends on binding to the IL-15
receptor. Our experiments show that binding of a biotinylated human
IL-15-immunoglobulin G2b IgG2b fusion protein was competed by the
addition of human recombinant IL-15 (rIL-15) or of human rIL-2,
suggesting that IL-15 binding to PMN might involve the IL-2R
and
IL-2R
chains, which have been shown to be constitutively expressed
by PMN. In addition, we show by reverse transcription-PCR and by flow
cytometry with a specific anti-IL-15R
chain monoclonal antibody that
PMN express the IL-15R
chain at the mRNA and protein levels.
Incubation with IL-15 activated PMN to secrete the chemotactic factor
IL-8, and the amount secreted was increased by costimulation with
heat-inactivated Candida albicans. In addition, IL-15
primed the metabolic burst of PMN in response to
formyl-methionyl-leucyl-phenylalanine but was not sufficient to trigger
the respiratory burst or to increase the production of superoxide in
PMN exposed to C. albicans. IL-15 also increased the
ability of PMN to phagocytose heat-killed C. albicans
organisms in a dose-dependent manner, without opsonization by
antibodies or complement-derived products. In the same concentration range, IL-15 was as effective as gamma interferon (IFN-
) and IL-2 in
increasing the C. albicans growth-inhibitory activity of
PMN. Taken together, these results suggest that IL-15 is a potent
stimulant of both proinflammatory and antifungal activities of PMN,
activating several antimicrobial functions of PMN involved in the
cellular response against C. albicans.
 |
INTRODUCTION |
Interleukin-15 (IL-15) is a recently
discovered cytokine that shares many biological activities with IL-2
and requires both
and
chains of the IL-2 receptor (IL-2R) for
binding and signaling (1, 22). However, the IL-15R complex
includes a specific
subunit (IL-15R
), distinct from the IL-2R
chain (11, 13). IL-15 stimulates the growth of activated T,
B, and NK cells and tumor-infiltrating lymphocytes (2, 23,
24), acts as a chemoattractant for T lymphocytes (40),
induces lymphokine-activated killer activity in NK cells, and induces
the generation of cytolytic effector cells (6, 11). There is
increasing evidence that IL-15 can also affect phagocytic cells. We
have recently shown that IL-15 acts as a proinflammatory cytokine that
induces monocytes to secrete IL-8 and monocyte chemotactic protein 1 (4), while other investigators have shown that it induces
morphological changes and delays apoptosis in polymorphonuclear
leukocytes (PMN) (20). One major difference between IL-2 and
IL-15 is their cellular source. Whereas IL-2 is produced principally by
T cells, IL-15 mRNA is present in macrophages and many nonlymphoid
tissues including placenta, skeletal muscle, and epithelial and
fibroblast cell lines (23). IL-15 expression is induced in
macrophages by microbial activators such as lipopolysaccharide,
mycobacteria, or Toxoplasma gondii (17, 30).
These observations suggest that IL-15 may play a role in the activation
of the immune response to infection. PMN form the first line of defense
in the inflammatory response against invading pathogens. Neutropenia or
PMN dysfunctions result in severe infections, including systemic
candidiasis (33). Inflammatory reactions result in the
production of cytokines such as tumor necrosis factor alpha,
granulocyte colony-stimulating factor, IL-2, gamma interferon
(IFN-
), and IL-8, which further attract and activate incoming PMN
(15, 16, 32). The main function of activated PMN is to
phagocytose and kill microbial pathogens. However, there is evidence
that they can also behave as a secondary source of cytokines (IL-8,
IL-12, and TNF-
) which can have important autocrine and paracrine
effects (12). In this study, we investigated the expression
of the
chain of the IL-15R on PMN and the effect of IL-15 on IL-8
secretion, superoxide anion release, phagocytosis, and candidacidal
activity. These studies are important to clarify the role of IL-15 in
the early steps of the innate immune response to invading pathogens.
 |
MATERIALS AND METHODS |
PMN isolation.
Whole blood obtained from healthy donors
after informed consent was diluted 1:2 with saline (0.9% NaCl),
layered on Lymphoprep (Nycomed; Pharma AS, Oslo, Norway), and
centrifuged at 400 × g for 30 min at room temperature.
The PMN layer, on the surface of the erythrocyte cell pellet, was
collected, and contaminating erythrocytes were lysed by hypotonic shock
in sterile distilled water for 30 s at room temperature. The cells
were washed twice in phosphate-buffered saline (PBS) before being
adjusted to the desired concentration. All cell suspensions contained
less than 1% monocytes as determined by monoesterase staining. Cell
viability was greater than 95% by trypan blue exclusion immediately
after isolation and after 6 and 18 h of incubation. The cells were
cultured in RPMI 1640 medium containing 10% heat-inactivated fetal
calf serum with 2 mM L-glutamine, 100 U of penicillin per
ml, 100 µg of streptomycin per ml, and 5 mM HEPES buffer (GIBCO
Laboratories, Grand Island, N.Y.); this is referred to as complete
medium. Therefore, unless otherwise indicated, all the experiments were
performed with few or no opsonins present.
Cytokines and reagents.
Recombinant human IL-15 was kindly
provided by Tony Troutt (Immunex Corp., Seattle, Wash.). To obtain
human IL-15-mouse immunoglobulin G2b (IgG2b) fusion protein, cDNA
encoding IL-15 was fused to genomic DNA encoding for the Fc portion of
mouse IgG2b. Biotinylation of human IL-15-mouse IgG2b fusion protein
resulted in higher stability of the cytokine without reduction of its
biological activity as determined by the CTLL proliferation assay
(10). Highly purified human IL-2 was kindly provided by
Cetus Corp. (Emeryville, Calif.); recombinant human IL-8 and IFN-
were from Peprotech (Rocky Hill, N.J.). fMLP
(formyl-methionyl-leucyl-phenylalanine) was from Sigma Chemical Co.
(St. Louis, Mo.). All reagents and media were shown to be free of
endotoxin by using a standard Limulus amebocyte lysate LAL
assay (BioWhittaker, Walkersville, Md.).
Flow cytometry analysis.
PMN were preincubated for 30 min at
4°C in PBS containing 2% goat serum plus 0.2% sodium azide, washed
twice with 1% bovine serum albumin (BSA) in PBS, and incubated (2 × 105 cells in 50 µl of 1% BSA in PBS) for 60 min at
4°C with the biotinylated IL-15-IgG2b fusion protein (1.3 µg per
sample) or with isotype-matched biotin-conjugated IgG (Pharmingen, San
Diego, Calif.) with or without the addition of unlabeled IL-15 or IL-2.
The cells were then washed twice with 1% BSA in PBS and further
incubated with fluorescein isothiocyanate (FITC)-conjugated avidin
(Sigma) for 20 min at 4°C. IL-15 binding was assessed by flow
cytometry. To determine the expression of the
chains of the IL-15R
and IL-2R, PMN were indirectly labeled for 20 min at 4°C with
anti-IL-15R
(clone M160; a kind gift of Tony Troutt, Immunex Corp.,
Seattle, Wash.) or anti-CD25 (Pharmingen) monoclonal antibodies (MAb)
followed by washing and incubation with FITC-conjugated goat anti-mouse Ig. R 1-30 (anti-
2-microglobulin) (26) was
used as a positive control. Labeled PMN were analyzed by flow
cytometric analysis with a FACScan (Becton Dickinson, Immunocytometry
System, San Jose, Calif.).
RT-PCR analysis.
RNA extraction and reverse
transcription-PCR (RT-PCR) analysis were performed as previously
described (9). Briefly, total RNA was purified with TRIzol
(GIBCO/BRL) as specified by the manufacturer. cDNA synthesis was
performed with 2 µg of RNA in a total volume of 20 µl containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 0.1 M
dithiothreitol, 40 U of RNase OUT RNase inhibitor (Life Technologies),
0.5 µg of oligo(dT), and 200 U of Superscript II reverse
transcriptase (Life Technologies). The reaction mixture was incubated
at 42°C for 50 min, and the reaction was stopped by heating at 90°C
for 5 min. A 2-µl aliquot of the cDNA obtained was amplified in a
50-µl reaction mixture containing 500 mM KCl, 100 mM Tris-HCl (pH
8.8), 25 mM MgCl2, 2 mM each deoxynucleoside triphosphate,
2 mg of BSA (Pharmacia) per ml, 200 nM each primer, and 5 U of
Taq DNA polymerase (Life Technologies). The mixture was
capped with 50 µl of sterile mineral oil. To ensure that equivalent amounts of cDNA were used in each reaction, PCR was also performed for
-actin from each sample and the cDNA was adjusted to equivalent levels. The following oligonucleotides were used in the PCR: IL-15R sense (5'-GCCAGCGCCACCCTCCACAGTAA-3') and IL-15R antisense
(5'-GCCAGCGGGGGAGTTTGCCTTGAC-3'), with cycling conditions of
1 min at 94°C, 1 min at 80°C, and 2 min at 72°C for 35 cycles;
and
-actin sense (5'-GAGCGGGAAATCGTGCGTGACATT-3') and
-actin antisense (5'-GAAGGTAGTTTCGTGGATGCC-3'), with
cycling conditions of 1 min at 94°C, 90 s at 62°C, and 2 min
at 72°C for 27 cycles. A sample (15 µl) of each PCR mixture was
electrophoresed through a 2% agarose gel and visualized with ethidium
bromide.
Culture of C. albicans.
Candida albicans CA2 was
kindly supplied by A. Cassone (Istituto Superiore di Sanità,
Rome, Italy) and was grown by weekly transfer onto fresh Sabouraud
dextrose agar (Biolife, Milan, Italy). CA2 is an agerminative strain
and grows as a pure yeast form in vitro at 28 or 37°C in conventional
mycologic media (27). For activation by microbial antigen,
C. albicans was washed in PBS, pelleted by centrifugation at
400 × g for 10 min, and killed by heating in boiling
water for 10 min.
Measurement of IL-8 protein production.
IL-8 in culture
supernatants was determined by using a commercially available
enzyme-linked immunosorbent assay (Amersham, Little Chalfont, England)
that allows the detection of IL-8 above 30 pg/ml.
Superoxide anion production.
Determination of superoxide
anion release by PMN was based on a sensitive assay that utilizes
dihydrorhodamine 123 (DHR-123) and was performed essentially as
described previously (35). Briefly, PMN (2 × 105 cells in 0.2 ml of medium) were preincubated at 37°C
for 15 min with the fluorescent probe DHR-123 (Molecular Probes, Inc.,
Princeton, N.J.) and with catalase (Sigma) before being subjected to
stimulation as described in Results. The fluorescence of DHR-123-loaded
cells did not substantially increase because of the intrinsic
fluorescence of heat-inactivated Candida cells;
Candida particles have a spontaneous fluorescence much lower
than that of DHR-123-loaded PMN (31).
After 30 min, the cells were analyzed with a FACScan. At least 5,000 events were measured, and on the basis of forward and side scatter, the
window for neutrophil-gated cells was set. Although this assay does not
provide quantitative data, the extent of superoxide anion production
can be estimated on the basis of the increase in green fluorescence
intensity of stimulated PMN in comparison to resting cells
(36). To calculate the percentage of cells that converted
DHR-123, a cutoff level was settled on the basis of the intrinsic
fluorescence of resting PMN.
Phagocytosis.
Heat-killed C. albicans was
fluorescein labeled as previously described (31). Briefly,
yeasts were resuspended in carbonate buffer (pH 10) containing 1 mg of
FITC per ml and incubated at room temperature for 2 h.
FITC-labeled Candida cells were separated from free
fluorescein by extensive washing with PBS. PMN (106
cells/ml) were incubated (10:1) with FITC-labeled Candida
cells for 30 min at 37°C, washed twice, and kept at 4°C in PBS
until examined by flow cytometry (FACScan). When necessary, C. albicans cells opsonized by incubation in 50% AB human serum at
37°C for 30 min and washed with PBS. Cells kept at 4°C with
FITC-labeled C. albicans were used as a negative control
because they do not phagocytose the organisms, as confirmed in parallel
examinations by fluorescence microscopy. PMN were gated on the basis of
their light-scattering properties; at least 10,000 events were
acquired. To differentiate uningested or cell surface-adherent
organisms from ingested organisms, ethidium bromide was added at 50 µg/ml. In fact, ingested particles of FITC-C. albicans
maintained their green fluorescence whereas particles bound to the cell
surface but not internalized were quenched by addition of the red
fluorochrome (18). The extent of phagocytosis was assessed
as the increase of the mean channel fluorescence of total PMN. An
aliquot of each sample was cytocentrifuged and stained with Giemsa for
a visual check of phagocytosis under a light microscope.
Growth inhibition of C. albicans.
To perform growth
inhibition experiments, PMN were resuspended in complete medium at
2 × 106 cells/ml, dispensed in triplicate (100 µl/well) in 96-well microtiter tissue culture plates, and treated
with increasing amounts (10 to 1,000 ng/ml) of human recombinant IL-15
or IL-2 (1,000 U/ml). IFN-
(500 U/ml) was used as a positive
control. After a 3-h incubation, C. albicans yeast was added
to achieve the effector-to-target ratio of 10:1. Preliminary
experiments performed in our laboratory showed that optimal sensitivity
was achieved with an effector-to-target ratio of 10:1 (data not shown).
C. albicans was also added to six wells without effector
cells to serve as controls. After a 3-h incubation at 37°C, Triton
X-100 (Sigma) (final concentration, 0.1%) was added to the wells.
Serial dilutions from each well were then made in distilled water and
plated (quadruplicate samples) on Sabouraud dextrose agar. After a 24-h
incubation at 37°C, the colonies were counted, and the results were
expressed as percent CFU inhibition, according to the formula (1 - CFU
in samples/CFU without PMN) × 100.
Statistical analysis.
Comparison among treatments was
performed by Student's t test or by analysis of variance as
appropriate. When a difference among multiple treatments was found, the
Newman-Keuls multiple-comparison test was used to identify which of the
means were significantly different from the others at the 0.05 significance level.
 |
RESULTS |
IL-15 binding to PMN.
To assess IL-15 binding, PMN were
incubated with biotinylated human IL-15-IgG2b fusion protein, alone or
in the presence of increasing concentrations of human recombinant IL-15
(rIL-15) or human rIL-2 (Fig. 1A). PMN
incubated with IL-15-IgG2b fusion protein showed a significant
increase in green fluorescence compared to cells incubated with control
IgG (P < 0.05). Both IL-15 and IL-2 can inhibit the
binding of IL-15-IgG2b fusion protein to PMN. Addition of a two fold
excess (1 µg) of unlabeled recombinant IL-15 was approximately twice
as effective as addition of an equal amount of IL-2 in blocking the
fusion protein binding (24 and 12% differences, respectively, in
median channel value shift to the left). These results suggest that
unstimulated PMN express IL-15-binding sites and that both IL-2R
and
IL-2R
may form part of the IL-15R complex. Besides
and
chains, IL-15R includes a distinct and specific IL-15R
chain which
has been described recently (22). We studied PMN expression
of the IL-15R
subunit at both RNA and protein levels (Fig. 1B and
C). By RT-PCR, IL-15R
mRNA was detected in unstimulated PMN. By FACS
analysis with a specific anti-IL-15R
chain MAb, the IL-15R
chain
was expressed at a detectable level by
20% of unstimulated PMN.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
PMN expression of the IL-15 receptor. (A) Binding of
IL-15 IgG 2b fusion protein to PMN. PMN were incubated with
biotin-conjugated IL-15 IgG2b fusion protein or with an equal amount of
isotype-matched biotinylated IgG (dark area) followed by staining with
streptavidin-FITC. Different amounts of IL-15 (panel 1) or IL-2 (panel
2) were added to PMN incubated with biotin-conjugated IL-15 IgG2b
fusion protein. The x axis represents the intensity of green
fluorescence expressed in a log scale as mean channel, and the
y axis represents the number of cells per channel. (B)
IL-15R expression determined by FACS analysis. PMN were stained with
MAb M160 (anti-IL-15R ) anti-CD25, or
anti- 2-microglobulin. (C) IL-15R mRNA expression.
cDNA derived from PMN (left lane) or mitogen-activated PBL (middle
lane) were amplified with primers specific for the IL-15R chain or
-actin, used as positive control. The right lane represents the
negative control.
|
|
Effects of IL-15 on IL-8 production by PMN.
PMN activation in
response to IL-15 was evaluated by measuring IL-8 production by PMN. As
shown in Fig. 2, a basal level of IL-8
was detectable in supernatants of PMN cultured in complete medium. The
addition of IL-15 at concentrations as low as 100 ng/ml led to
increased IL-8 release after 6 h of stimulation, and greater
amounts were detectable after 24 h. We then studied the effects of
C. albicans on IL-8 release following PMN activation by
IL-15. Heat-inactivated C. albicans alone was as potent as 1,000 ng of IL-15 per ml. PMN treated with IL-15 and heat-killed C. albicans released significantly greater amounts of IL-8.
These results indicate that IL-15 synergizes with inactivated C. albicans in inducing IL-8 release by PMN.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
IL-8 production by IL-15-stimulated PMN. Cells were
stimulated with different concentrations of IL-15 (100 or 1,000 ng/ml),
with IL-2 (50 or 1,000 U/ml), or with medium alone with or without the
addition of heat-inactivated Candida cells. Supernatants
were collected after 6 h (A) or 24 h (B) and assayed for IL-8
by enzyme-linked immunosorbent assay. IL-8 concentrations are presented
on the y axis as the mean ± SE of values from three
experiments. Asterisks indicate a significant increase of IL-8
production (P < 0.05).
|
|
Effects of IL-15 on superoxide anion generation by PMN.
Cytokines stimulate PMN by inducing the secretion of proinflammatory
cytokines and by activating their antimicrobial oxidative pathway
(3, 33). To determine whether IL-15 stimulates superoxide anion production by PMN, we used a fluorescent probe (DHR-123) that
increases its green fluorescence when exposed to reactive oxygen
(35). PMN were preincubated with DHR-123 and then stimulated with IL-15 (1,000 ng/ml), IL-2 (1,000 U/ml), fMLP (10 nM), or medium
alone. After 30 min, the fluorescence intensity of resting and
stimulated PMN was assessed by FACS. As shown in Fig.
3, the percentages (mean ± standard
error [SE]) of positive PMN from four independent donors increased
from 3% ±2% to 89% ±4% upon fMLP stimulation (P < 0.05), while neither IL-15 nor IL-2 induced superoxide anion
production. These results were confirmed by the cytochrome c
reduction method (data not shown). In addition, to examine if IL-15
synergized with either fMLP or C. albicans in superoxide
anion release, PMN were incubated for 3 h with IL-15 (1,000 ng/ml), IFN-
(500 U/ml), or medium alone. The cells were then loaded
with DHR-123 and stimulated with heat-killed C. albicans or
10 nM fMLP for 30 min. As shown in Fig.
4, fMLP induced superoxide anion
production in PMN preincubated with medium. The percentages (mean ± SE) of positive cells from three separate donors increased from 2%
±1% to 25% ±7% upon fMLP stimulation (P < 0.05).
C. albicans alone could also induce detectable levels of
superoxide, but to a lower extent (2% ± 1% and 8% ± 4%,
respectively). Priming of PMN with IL-15 significantly augmented the
PMN oxidative burst in response to fMLP (50% ± 5% versus 25% ± 7%; P < 0.05) but not to C. albicans (11% ± 3% versus 8% ± 4). IFN-
, used as control, was able to prime
PMN for additional induction of the oxidative metabolite with either
fMLP (53% ± 11% versus 25% ± 7%; P < 0.05) or
C. albicans, although to a lower extent (19% ± 3% versus
8% ± 4%; P < 0.05).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of the respiratory burst in IL-15-stimulated
PMN. PMN preincubated with DHR-123 were stimulated at 37°C with fMLP
(10 nM), IL-15 (1,000 ng/ml), IL-2 (1,000 U/ml), or medium alone
(dotted lines) for 30 min, and green fluorescence was assessed by FACS.
The x axis represents the intensity of green fluorescence
expressed in a log scale as mean channel, and the y axis
represents the number of cells per channel.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Priming of the respiratory burst by IL-15. PMN were
preincubated at 37°C with IL-15 (1,000 ng/ml), IFN- (500 U/ml), or
medium alone for 3 h. They were then loaded with DHR-123 and
stimulated with heat-killed Candida
(PMN-to-Candida ratio, 10:1), fMLP (10 nM), or medium alone.
After 30 min, superoxide anion production was evaluated by flow
cytometry as an increase in green fluorescence intensity. The
x axis represents the intensity of green fluorescence
expressed in a log scale as mean channel, and the y axis
represents the number of cells per channel.
|
|
Enhancement of C. albicans phagocytosis by IL-15.
We next investigated whether IL-15 stimulation of PMN increased the
rate of phagocytosis of C. albicans. PMN were preincubated with increasing concentrations of IL-15 (10 to 1,000 ng/ml), IL-2 (50 or 1,000 U/ml), or medium alone; after 30 min, heat-inactivated FITC-conjugated C. albicans was added. As shown in Fig.
5, IL-15 induced a dose-dependent
increase in phagocytosis by PMN, as indicated by the increase in the
green fluorescence mean channel from three independent experiments. As
previously reported, IL-2 did not induce a significant increase in PMN
phagocytosis at 50 U/ml (19) but was active at 1,000 U/ml.
The percentage (mean ± SE) of PMN that phagocytosed C. albicans increased from 45% ± 3% to 66% ± 4% upon IL-15
stimulation or to 56% ±3% upon IL-2 stimulation. These results
indicate that IL-15 significantly increased the number of phagocytosing
cells (P < 0.05) as well as the rate of phagocytosis.
In the presence of opsonins, basal phagocytosis was high in resting
cells (82% ± 4%), but it increased in IL-15-stimulated PMN (94% ± 1%) (P < 0.05); the mean channel fluorescence
increased from 60 ± 6 to 180 ± 10 (P < 0.05).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 5.
Phagocytosis of heat-inactivated Candida by
PMN stimulated with IL-15. PMN were preincubated with different
concentrations of IL-15 (from 10 to 1,000 ng/ml), IL-2 (50 or 1,000 U/ml), or medium alone for 3 h. Heat-inactivated FITC-labeled
Candida cells were then added to the cultures at a
PMN-to-Candida ratio of 10:1, and the cultures were further
incubated for 30 min at 37°C before the extent of phagocytosis was
assessed by flow cytometry in the presence of ethidium bromide. The
extent of phagocytosis is represented on the y axis as the
mean ± SE of green fluorescence mean channel from three
independent experiments. Asterisks indicate a significant increase in
phagocytosis (P < 0.05).
|
|
Enhancement of PMN candidacidal activity by IL-15.
To assess
the effect of IL-15 on the antifungal activity of PMN, cells were
incubated for 3 h with increasing concentrations of IL-15 (10 to
1,000 ng/ml) before the addition of C. albicans. Untreated
PMN showed low levels of antifungal activity, which were increased by
IL-15 treatment (Fig. 6A). PMN activation
by IL-15 was dose dependent; concentrations as low as 100 ng/ml were sufficient to increase the killing of yeasts by PMN. The effect of
IL-15 on the antifungal activity of PMN was compared with the effect of
other PMN stimulants such as IFN-
and IL-2. PMN were preincubated
with IFN-
(500 U/ml), IL-2 (1,000 U/ml), or IL-15 (1,000 ng/ml), of
concentrations known to induce maximal PMN activation. The PMN were
then incubated with C. albicans for assessment of function.
Figure 6B shows that IL-15 had similar potency to IFN-
and IL-2.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 6.
Enhancement of PMN anti-Candida activity by
IL-15. (A) PMN were incubated with increasing concentrations of IL-15
(from 10 to 1,000 ng/ml) for 3 h, exposed to C. albicans, and assayed for anti-Candida activity as
described in the text. (B) PMN were stimulated for 3 h with
IFN- (500 U/ml), IL-2 (1,000 U/ml), IL-15 (1,000 ng/ml), or medium
alone before their anti-Candida activity was assessed.
Results represent mean percent growth inhibition ± SE for three
independent experiments. Asterisks indicate a significant increase in
the anti-Candida activity (P < 0.05).
|
|
 |
DISCUSSION |
In this paper, we demonstrate that IL-15 enhances the response of
PMN to the yeast C. albicans. Our binding experiments have shown that both IL-15 and IL-2 partially inhibited the binding of
IL-15-IgG2b fusion protein to PMN, suggesting that the receptor complexes of both of these cytokines involve the IL-2R
and IL-2R
chains, as previously reported (21). However, IL-2 and IL-15 utilize different
-chain receptor subunits (11, 22). By
using specific MAbs, we showed that, unlike the IL-2R
chain, the
IL-15R
chain is detectable on unstimulated PMN, although at a low
level (15, 25). Taken together, these results can account
for the fact that IL-2 competed less than IL-15 in our binding
experiments. They also corroborate the hypothesis of Girard et al.,
which proposes that PMN express a specific IL-15R
chain, as
suggested by the different effects of the two cytokines in the
induction of morphological alterations and in the delay of apoptosis in
PMN (20).
PMN microbicidal action involves both oxidative and nonoxidative
pathways. Reactive oxygen radicals are released when PMN interact with
microbial pathogens or are stimulated via G-protein-coupled receptors
(e.g., fMLP receptor) (3, 33). Cytokines such as IFN-
or
G-CSF alone do not induce the respiratory burst, but preincubation of
PMN with IFN-
or G-CSF primes cells for the induction of oxygen
radicals by fMLP or by C. albicans. IL-15 was also effective
in enhancing the oxidative respiratory burst in response to fMLP,
although it failed to induce superoxide anions by itself and to prime
PMN for Candida induction of the oxygen radicals. This
suggests that either the IL-15 enhancement of PMN anti-Candida activity is mediated through a nonoxidative
pathway or the priming effect is not detectable under our experimental conditions. IL-2 is equally effective in the activation of antifungal functions of PMN (15). As reported by Djeu et al.
(15), IL-2-mediated anti-Candida activity is not
related to activation of the metabolic burst because IL-2 does not
display any priming activity on the respiratory burst elicited by fMLP.
These results indicate that IL-2 and IL-15, although sharing activating
properties on PMN, might utilize distinct stimulatory pathways,
probably because these two cytokines may activate common receptor
components such as the
and
chains of the IL-2R or distinct
receptor subunits like the IL-15R
chain.
Phagocytosis is considered to be a required step for the intracellular
killing of the vegetative form of Candida. We have shown
that IL-15 induces a dose-dependent increase of phagocytosis of
C. albicans at the same concentration range at which this
cytokine induces PMN candidacidal activity. This result suggests that
IL-15 may stimulate the phagocytosis and the consequent intracellular killing of yeast involving nonoxidative mechanisms such as lysosomal antimicrobial peptides and enzymes. We have indirect evidence that the
activation of PMN by IL-15 may be associated with the release of
antimicrobial peptides (e.g., defensins, CAP37/azurocidin, and
lactoferrin) (8). In fact, we observed that PMN activated by
IL-15 display an increased expression of CD11b, a marker of specific
granules, suggesting that IL-15 probably induces neutrophil degranulation (29a). Another possible mechanism that might
be involved in PMN activation by IL-15 is dependent on the expression of the inducible enzyme nitric oxide synthase (iNOS). Although resting
PMN do not express iNOS, IL-15 may be capable of inducing its
expression. However, in other cell types, the kinetics of iNOS
expression are very different from those observed for the anti-Candida activity of IL-15 (28, 38, 39, 41).
Besides its antimicrobial activities, IL-15 has proinflammatory
properties that may enhance the extent of its anti-Candida
activity in vivo. We showed that IL-15 induces the secretion of the
neutrophil chemotactic factor IL-8 within 6 h of stimulation. IL-8
is secreted mostly by monocytes and endothelial cells, but it is also
expressed, in smaller amounts, by PMN (7, 37). We recently
reported that IL-15 stimulates monocytes to express IL-8 at both the
mRNA and protein levels in the same concentration range that is
effective in neutrophil activation (4). This suggests that
the production of IL-15 in the early steps of the inflammatory response
to pathogens might increase the amount of PMN infiltrating the tissues.
Besides being a chemotactic factor for PMN, IL-8 itself stimulates
antimicrobial functions by enhancing degranulation and
anti-Candida activity of PMN (5, 16). Since IL-15
induced IL-8 secretion, we tested the possibility that IL-8 mediates
the enhancement of anti-Candida activity induced by IL-15;
however, we could not detect any change of IL-15 activity on PMN when
IL-8 neutralizing antibodies were added to the culture (data not
shown). These results suggest that under our experimental conditions
the antifungal activity of IL-15 did not depend on IL-8 secretion. This
does not contradict the observed antifungal activity of IL-8, because
the concentrations of IL-8 that we detected after 6 h of
stimulation with IL-15 are not optimal for activation of PMN
anti-Candida activity (16). Upon longer
stimulation in vitro or in vivo, IL-8 secretion might be important for
the anti-Candida effect of IL-15, but it is likely that in
our experimental setting, IL-15 directly activated PMN against C. albicans. Unlike IL-2, IL-15 expression is induced in macrophages
by microbial activators such as LPS, mycobacteria, or Toxoplasma
gondii (17). We are currently investigating the mechanisms that regulate IL-15 expression by monocytes upon infection with fungi or other microbial pathogens. We found that C. albicans up-regulates IL-15 mRNA expression in human monocytes
(29b). Taken as a whole, these results suggest that IL-15
may be expressed in the early steps of the aspecific immune response to
bacteria and yeasts. IL-15 produced by activated tissue-resident
macrophages or by fibroblasts may activate PMN recruited to the site of
infection to kill pathogens and determine an additional infiltration of PMN through IL-8 release. In addition, IL-15, which is chemotactic for
T cells, may induce T-cell infiltration and maintain their proliferative response to Candida antigens. However, in
vivo, IL-15 anti-Candida activity may be biased by other
factors such as cytokines, Igs, or complement factors that could affect
the response to IL-15; indeed, Vazquez et al. have recently reported that IL-15 enhances monocyte activity against opsonized
Candida cells (34). Our results suggest that
IL-15 may play a significant role in human innate immunity against
C. albicans and may offer an adjunct for use in the
prevention and treatment of fungal infections in immunocompromised
patients with chronic granulomatous disease (CGD), a genetically
inherited disease characterized by increased susceptibility to fungal
infections (14). This is dependent on the lack of superoxide
anion production by phagocytic cells because of mutations of genes
encoding the subunits of NADPH oxidase. In patients with CGD, IFN-
is currently used for prophylaxis of infections. On the basis of our
results, IL-15 might potentiate the antimicrobial functions of PMN by a
nonoxidative pathway in CGD patients. It will be possible to test this
hypothesis since animal models of CGD have recently become available
(29).
 |
ACKNOWLEDGMENTS |
We thank Antonio Cassone for helpful discussions.
This work was partly supported by a grant from the First National
Project on Tuberculosis, (contract 783, Istituto Superiore di
Sanità, Rome, Italy) and by the Italian Ministry of University and Scientific Research (60% grant). R.B. was supported by a
fellowship from Telethon, (Rome, Italy).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Microbiologia, Via Santena 9, 10126 Turin, Italy. Phone: 39 11 670.6609. Fax: 39 11 663.6436.
Editor: T. R. Kozel
 |
REFERENCES |
| 1.
|
Anderson, D. M.,
S. Kumaki,
M. Ahdieh,
J. Bertles,
M. Tometsko,
A. Loomis,
J. Giri,
N. G. Copeland,
D. J. Gilbert,
N. A. Jenkins, et al.
1995.
Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes.
J. Biol. Chem.
270:29862-29869[Abstract/Free Full Text].
|
| 2.
|
Armitage, R. J.,
B. M. Macduff,
J. Eisenman,
R. Paxton, and K. H. Grabstein.
1995.
IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation.
J. Immunol.
154:483-490[Abstract].
|
| 3.
|
Babior, B. M.
1988.
Phagocytic defects.
Hematol. Oncol. Clin. North Am.
2:201-237[Medline].
|
| 4.
|
Badolato, R.,
A. Negro Ponzi,
M. Millesimo,
L. D. Notarangelo, and T. Musso.
1997.
Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes.
Blood
90:2804-2809[Abstract/Free Full Text].
|
| 5.
|
Baggiolini, M.,
B. Dewald, and B. Moser.
1994.
Interleukin-8 and related chemotactic cytokines CXC and CC chemokines.
Adv. Immunol.
55:97-179[Medline].
|
| 6.
|
Bamford, R. N.,
A. J. Grant,
J. D. Burton,
C. Peters,
G. Kurys,
C. K. Goldman,
J. Brennan,
E. Roessler, and T. A. Waldmann.
1994.
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
Proc. Natl. Acad. Sci. USA
91:4940-4944[Abstract/Free Full Text].
|
| 7.
|
Bazzoni, F.,
M. A. Cassatella,
F. Rossi,
M. Ceska,
B. Dewald, and M. Baggiolini.
1991.
Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8.
J. Exp. Med.
173:771-774[Abstract/Free Full Text].
|
| 8.
|
Borregaard, N., and J. B. Cowland.
1997.
Granules of the human neutrophilic polymorphonuclear leukocyte.
Blood
89:3503-3521[Free Full Text].
|
| 9.
|
Bulfone-Paus, S.,
H. Durkop,
R. Paus,
H. Krause,
T. Pohl, and A. Onu.
1997.
Differential regulation of human T lymphoblast functions by IL-2 and IL-15.
Cytokine
9:507-513[Medline].
|
| 10.
|
Bulfone-Paus, S.,
D. Ungureanu,
T. Pohl,
G. Lindner,
H. Krause,
R. Paus, and U. Kunzendorf.
1997.
Interleukin-15 protects from lethal apoptotic cell death in mice.
Nat. Med.
3:1124-1128[Medline].
|
| 11.
|
Carson, W. E.,
J. G. Giri,
M. J. Lindemann,
M. L. Linett,
M. Ahdieh,
R. Paxton,
D. Anderson,
J. Eisenmann,
K. Grabstein, and M. A. Caligiuri.
1994.
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
J. Exp. Med.
180:1395-1403[Abstract/Free Full Text].
|
| 12.
|
Cassatella, M. A.
1995.
The production of cytokines by polymorphonuclear neutrophils.
Immunol. Today
16:21-26[Medline].
|
| 13.
|
Chae, D. W.,
Y. Nosaka,
T. B. Strom, and W. Maslinski.
1996.
Distribution of IL-15 receptor chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression.
J. Immunol.
157:2819.
|
| 14.
|
Cohen, M. S.,
R. E. Isturiz,
H. L. Malech,
R. K. Root,
C. M. Wilfert,
L. Gutman, and R. H. Buckley.
1981.
Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defence against fungi.
Am. J. Med.
71:59-66[Medline].
|
| 15.
|
Djeu, J. Y.,
J. H. Liu,
S. Wei,
H. Rui,
C. A. Pearson,
W. J. Leonard, and D. K. Blanchard.
1993.
Function associated with IL-2 receptor- on human neutrophils.
J. Immunol.
150:960-970[Abstract].
|
| 16.
|
Djeu, J. Y.,
K. Matsushima,
J. J. Oppenheim,
K. Shiotsuki, and D. K. Blanchard.
1990.
Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8.
J. Immunol.
144:2205-2210[Abstract].
|
| 17.
|
Doherty, T. M.,
R. A. Seder, and A. Sher.
1996.
Induction and regulation of IL-15 expression in murine macrophages.
J. Immunol.
156:735-741[Abstract].
|
| 18.
|
Fattorossi, A.,
R. Nisini,
J. G. Pizzolo, and R. D'Amelio.
1989.
New, simple flow cytometry technique to discriminate between internalized and membrane-bound particles in phagocytosis.
Cytometry
10:320-325[Medline].
|
| 19.
|
Girard, D.,
J. Gosselin,
D. Heitz,
R. Paquin, and A. D. Beaulieu.
1995.
Effects of interleukin-2 on gene expression in human neutrophils.
Blood
88:1170-1176.
|
| 20.
|
Girard, D.,
M. Paquet,
R. Paquin, and A. D. Beaulieu.
1996.
Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15.
Blood
88:3176-3184[Abstract/Free Full Text].
|
| 21.
|
Giri, J. G.,
M. Ahdieh,
J. Eisenman,
K. Shanebeck,
K. Grabstein,
S. Kumaki,
A. Namen,
L. S. Park,
D. Cosman, and D. Anderson.
1994.
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.
EMBO J.
13:2822-2830[Medline].
|
| 22.
|
Giri, J. G.,
S. Kumaki,
M. Ahdieh,
D. J. Friend,
A. Loomis,
K. Shanebeck,
R. DuBose,
D. Cosman,
L. S. Park, and D. M. Anderson.
1995.
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor.
EMBO J.
14:3654-3663[Medline].
|
| 23.
|
Grabstein, K. H.,
J. Eisenman,
K. Shanebeck,
C. Rauch,
S. Srinivasan,
V. Fung,
C. Beers,
J. Richardson,
M. A. Schoenborn,
M. Ahdieh, et al.
1994.
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.
Science
264:965-968[Abstract/Free Full Text].
|
| 24.
|
Lewko, W. M.,
T. L. Smith,
D. J. Bowman,
R. W. Good, and R. K. Oldham.
1995.
Interleukin-15 and the growth of tumor-derived activated T-cells.
Cancer Biother.
10:13-20[Medline].
|
| 25.
|
Liu, J. H.,
S. Wei,
D. Ussery,
P. K. Epling-Burnette,
W. J. Leonard, and J. Y. Djeu.
1994.
Expression of interleukin-2 receptor chain on human neutrophils.
Blood
84:3870-3875[Abstract/Free Full Text].
|
| 26.
|
Malavasi, F.,
F. Calligaris-Cappio,
P. Dellabona,
P. Richiardi, and A. O. Carbonara.
1984.
Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.
Hum. Immunol.
9:9[Medline].
|
| 27.
|
Mattia, E.,
G. Carruba,
L. Angiolella, and A. Cassone.
1982.
Induction of germ tube formation by N-acetyl-D-glucosamine in Candida albicans: uptake of inducer and germinative response.
J. Bacteriol.
152:555-562[Abstract/Free Full Text].
|
| 28.
|
Melillo, G.,
L. S. Taylor,
A. Brooks,
G. W. Cox, and L. Varesio.
1996.
Regulation of inducible nitric oxide synthase expression in IFN- -treated murine macrophages cultured under hypoxic conditions.
J. Immunol.
157:2638-2644[Abstract].
|
| 29.
|
Morgesten, D. E.,
M. A. Gifford,
C. M. Doerschuk, and M. C. Dinauer.
1997.
Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus.
J. Exp. Med.
185:207-218[Abstract/Free Full Text].
|
| 29a.
| Musso, T., et al. Unpublished data.
|
| 29b.
| Musso, T., et al. Unpublished data.
|
| 30.
|
Nishimura, H.,
K. Hiromatsu,
N. Kobayashi,
K. H. Grabstein,
R. Paxton,
K. Sugamura,
J. A. Bluestone, and Y. Yoshikai.
1996.
IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection.
J. Immunol.
156:663-669[Abstract].
|
| 31.
|
Perticari, S.,
G. Presani,
M. G. Mangiarotti, and E. Banfi.
1991.
Simultaneous flow cytometric method to measure phagocytosis and oxidative products by neutrophils.
Cytometry
12:687-691[Medline].
|
| 32.
|
Peveri, P.,
A. Waltz,
B. Dewal, and M. Baggiolini.
1988.
A novel neutrophil activating factor produced by human mononuclear phagocytes.
J. Exp. Med.
167:1883-1885[Abstract/Free Full Text].
|
| 33.
|
Thomas, E. L.,
R. I. Lehrer, and R. F. Rest.
1988.
Human neutrophil antimicrobial activity.
Rev. Infect. Dis.
10:S450-451.
|
| 34.
|
Vazquez, N.,
T. J. Walsh,
D. Friedman,
S. J. Chanock, and C. A. Lyman.
1998.
Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.
Infect. Immun.
66:145-150[Abstract/Free Full Text].
|
| 35.
|
Vowells, S. J.,
S. Sekhsaria,
H. L. Malech,
M. Shalit, and T. A. Fleisher.
1995.
Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes.
J. Immunol. Methods
178:89-97[Medline].
|
| 36.
|
Waddel, T. K.,
L. Fialkow,
C. K. Chan,
T. K. Kishimoto, and G. P. Downey.
1994.
Potentiation of the oxidative burst of human neutrophils. A signaling role for L-selectin.
J. Biol. Chem.
269:18485-18491[Abstract/Free Full Text].
|
| 37.
|
Wei, S.,
J. D. Liu,
D. K. Blanchard, and J. Y. Djeu.
1994.
Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2.
J. Immunol.
152:3630-3636[Abstract].
|
| 38.
|
Weinberg, J. B.,
M. A. Misukonis,
P. J. Shami,
S. N. Mason,
D. L. Sauls,
W. A. Dittman,
E. R. Wood,
G. K. Smith,
B. McDonald,
K. E. Bachus,
A. F. Haney, and D. L. Granger.
1995.
Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages.
Blood
86:1184-1195[Abstract/Free Full Text].
|
| 39.
|
Wheeler, M. A.,
D. S. Shannon,
G. Garcia-Cardena,
C. F. Nathan,
R. M. Weiss, and W. C. Sessa.
1997.
Bacterial infection induces nitric oxide synthase in human neutrophils.
J. Clin. Invest.
99:110-116[Medline].
|
| 40.
|
Wilkinson, P. C., and F. Y. Liew.
1995.
Chemoattraction of human blood T lymphocytes by interleukin-15.
J. Exp. Med.
181:1255-1259[Abstract/Free Full Text].
|
| 41.
|
Yan, L.,
W. R. Vandivier,
A. F. Suffredini, and R. L. Danner.
1994.
Human polymorphonuclear leukocytes lack detectable nitric oxide synthase activity.
J. Immunol.
153:1825-1834[Abstract].
|
Infect Immun, June 1998, p. 2640-2647, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Small, C.-L., McCormick, S., Gill, N., Kugathasan, K., Santosuosso, M., Donaldson, N., Heinrichs, D. E., Ashkar, A., Xing, Z.
(2008). NK Cells Play a Critical Protective Role in Host Defense against Acute Extracellular Staphylococcus aureus Bacterial Infection in the Lung. J. Immunol.
180: 5558-5568
[Abstract]
[Full Text]
-
Baranda, L., de la Fuente, H., Layseca-Espinosa, E., Portales-Perez, D., Nino-Moreno, P., Valencia-Pacheco, G., Abud-Mendoza, C., Alcocer-Varela, J., Gonzalez-Amaro, R.
(2005). IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford)
44: 1507-1513
[Abstract]
[Full Text]
-
Ozawa, A., Tada, H., Sugawara, Y., Uehara, A., Sasano, T., Shimauchi, H., Takada, H., Sugawara, S.
(2004). Endogenous IL-15 Sustains Recruitment of IL-2R{beta} and Common {gamma} and IL-2-Mediated Chemokine Production in Normal and Inflamed Human Gingival Fibroblasts. J. Immunol.
173: 5180-5188
[Abstract]
[Full Text]
-
Bouchard, A., Ratthe, C., Girard, D.
(2004). Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. J. Leukoc. Biol.
75: 893-900
[Abstract]
[Full Text]
-
Kobayashi, S. D., Voyich, J. M., Braughton, K. R., DeLeo, F. R.
(2003). Down-Regulation of Proinflammatory Capacity During Apoptosis in Human Polymorphonuclear Leukocytes. J. Immunol.
170: 3357-3368
[Abstract]
[Full Text]
-
Fierer, J., Swancutt, M. A., Heumann, D., Golenbock, D.
(2002). The Role of Lipopolysaccharide Binding Protein in Resistance to Salmonella Infections in Mice. J. Immunol.
168: 6396-6403
[Abstract]
[Full Text]
-
Goldenberg, D. T., Holland, G. N., Cumberland, W. G., Fisher, T. C., Folz, I.-C., Wang, R. C., Terry, B. G., Moe, A. A., Kramer, F., Lim, J. I., Rao, N. A., Meiselman, H. J.
(2002). An Assessment of Polymorphonuclear Leukocyte Rigidity in HIV-Infected Individuals after Immune Recovery. IOVS
43: 1857-1861
[Abstract]
[Full Text]
-
Fehniger, T. A., Caligiuri, M. A.
(2001). Interleukin 15: biology and relevance to human disease. Blood
97: 14-32
[Full Text]
-
Mastroianni, C. M., d'Ettorre, G., Forcina, G., Lichtner, M., Mengoni, F., D'Agostino, C., Corpolongo, A., Massetti, A. P., Vullo, V.
(2000). Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. Blood
96: 1979-1984
[Abstract]
[Full Text]
-
Ruckert, R., Asadullah, K., Seifert, M., Budagian, V. M., Arnold, R., Trombotto, C., Paus, R., Bulfone-Paus, S.
(2000). Inhibition of Keratinocyte Apoptosis by IL-15: A New Parameter in the Pathogenesis of Psoriasis?. J. Immunol.
165: 2240-2250
[Abstract]
[Full Text]
-
Musso, T., Calosso, L., Zucca, M., Millesimo, M., Ravarino, D., Giovarelli, M., Malavasi, F., Ponzi, A. N., Paus, R., Bulfone-Paus, S.
(1999). Human Monocytes Constitutively Express Membrane-Bound, Biologically Active, and Interferon-{gamma}-Upregulated Interleukin-15. Blood
93: 3531-3539
[Abstract]
[Full Text]